Previous 10 | Next 10 |
2024-01-29 02:13:56 ET More on Dare Bioscience Daré Bioscience to eliminate CFO and CCO roles to rein in costs Organon says Xaciato now available nationwide Seeking Alpha’s Quant Rating on Dare Bioscience Historical earnings data for Dare Biosc...
2024-01-26 16:50:49 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript Organon says Xaciato now available nationwide Dare Bioscience secures $12M in royalty-backed investment structure Seeking Alpha’s Quant Ra...
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Comme...
SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live...
2024-01-10 10:04:45 ET More on Dare Bioscience, Organon, etc. Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90%...
SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and pr...
2023-12-26 08:36:16 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript Dare Bioscience Q3 2023 Earnings Preview Daré Bioscience's stock rises ~15% on $1.8M milestone from Organon for Xaciato Seeking Alpha’...
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million thro...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1. DARE-PDM1 i...
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Dar...
News, Short Squeeze, Breakout and More Instantly...
Dare Bioscience Inc. Company Name:
DARE Stock Symbol:
NASDAQ Market:
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub , a regional hub of ARPANET-H , a nationwide health innovation network launched by ...
Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results. H&E ...
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, X...